Advertisement

Metabolic Brain Disease

, 24:453 | Cite as

Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study

  • S. Arpin
  • E. Lagrue
  • S. Bodard
  • S. Chalon
  • P. Castelnau
Original Paper

Abstract

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model provides a valuable paradigm of the energy deficiency disorders found in childhood. In such disorders, anticonvulsants may provide neuroprotection by modulating cellular energy consumption and by exerting favorable pleiotropic effects on neuronal survival. To verify such hypothesis, we tested the effects of levetiracetam, vigabatrin, gabapentine, pregabaline, tiagabine, clonazepam and lamotrigine on neuroprotection in the MPTP mouse model. The membrane dopamine transporter (DAT) density, which provides a reliable index of dopaminergic neurons survival in the basal ganglia, was assessed by semi-quantitative autoradiography of the striatum. Unlike all other anticonvulsants tested, lamotrigine provided a significant and dose-dependent neuroprotection in these experimental conditions. Lamotrigine, a widely used and well-tolerated molecule in children, could provide neuroprotection in various energy deficiency disorders.

Keywords

Basal ganglia Mitochondria MPTP Leigh syndrome Neuroprotection Anticonvulsant 

Notes

Acknowledgments

The authors thank M.-C. Furon for technical assistance with animal handling, L. Garreau, M-P. Vilar, and J. Vergotte for contributive support on experiments, and C. Hoinard for expert contribution to statistical analysis. The authors also thank F. Paillard for editing the manuscript. This work was supported by fellowships from the Fondation pour la Recherche Medicale (FRM) and from the DRASS Region Centre, France, to S. Arpin.

References

  1. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog Neurobiol 60:409–470CrossRefPubMedGoogle Scholar
  2. Andre V, Ferrandon A, Marescaux C, Nehlig A (2001) Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 47:99–117CrossRefPubMedGoogle Scholar
  3. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y (2001a) Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231–238CrossRefPubMedGoogle Scholar
  4. Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, Imai Y (2001b) Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 918:176–181CrossRefPubMedGoogle Scholar
  5. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298–304CrossRefPubMedGoogle Scholar
  6. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646–653CrossRefPubMedGoogle Scholar
  7. Cavanagh JB, Harding BN (1994) Pathogenic factors underlying the lesions in Leigh’s disease. Tissue responses to cellular energy deprivation and their clinico-pathological consequences. Brain 117(Pt 6):1357–1376CrossRefPubMedGoogle Scholar
  8. Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JC, Guilloteau D (1999) Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291:648–654PubMedGoogle Scholar
  9. Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M, Siliquini S, Autuori A, Picconi B, Spillantini MG, Fedele E, Pittaluga A, Raiteri M, Calabresi P (2008) Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28:8040–8052CrossRefPubMedGoogle Scholar
  10. D’Astous M, Morissette M, Di Paolo T (2004) Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 47:1180–1188CrossRefPubMedGoogle Scholar
  11. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K (1998) Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 358:351–359CrossRefPubMedGoogle Scholar
  12. Gibbs JE, Walker MC, Cock HR (2006) Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 47:469–478CrossRefPubMedGoogle Scholar
  13. Groenendaal F, Benders MJ, de Vries LS (2006) Pre-wallerian degeneration in the neonatal brain following perinatal cerebral hypoxia-ischemia demonstrated with MRI. Semin Perinatol 30:146–150CrossRefPubMedGoogle Scholar
  14. Iqbal S, Baziany A, Gordon S, Wright S, Hussain M, Miyashita H, Shuaib A, Hasan Rajput A (2002) Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res 946:162–170CrossRefPubMedGoogle Scholar
  15. Jones-Humble SA, Morgan PF, Cooper BR (1994) The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson’s disease. Life Sci 54:245–252CrossRefPubMedGoogle Scholar
  16. Kapoor R (2008) Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 274:54–56CrossRefPubMedGoogle Scholar
  17. Kilbourn MR, Kuszpit K, Sherman P (2000) Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35:250–255CrossRefPubMedGoogle Scholar
  18. Lagrue E, Chalon S, Bodard S, Saliba E, Gressens P, Castelnau P (2007) Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatr Res 62:14–19CrossRefPubMedGoogle Scholar
  19. Lagrue E, Abert B, Nadal L, Tabone L, Bodard S, Medja F, Lombes A, Chalon S, Castelnau P (2009) MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood. Metab Brain Dis 24:321–335CrossRefPubMedGoogle Scholar
  20. Lee WT, Shen YZ, Chang C (2000) Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience 95:89–95CrossRefPubMedGoogle Scholar
  21. Li X, Bijur GN, Jope RS (2002) Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4:137–144CrossRefPubMedGoogle Scholar
  22. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142–149CrossRefPubMedGoogle Scholar
  23. Meldrum BS (1996) Update on the mechanism of action of antiepileptic drugs. Epilepsia 37:S4–S11CrossRefPubMedGoogle Scholar
  24. Obrenovitch TP, Urenjak J (1998) Glutamate release inhibitors: a critical assessment of their action mechanism. Amino Acids 14:143–150CrossRefPubMedGoogle Scholar
  25. Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F (2007) The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 48:1842–1849CrossRefPubMedGoogle Scholar
  26. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135–142PubMedGoogle Scholar
  27. Sabers A, Gram L (2000) Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 60:23–33CrossRefPubMedGoogle Scholar
  28. Saudubray J-M, Charpentier C (1995) Clinical phenotypes: diagnosis/algoritms. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. Mc Graw-Hill, New York, pp 327–400Google Scholar
  29. Schulz JB, Matthews RT, Henshaw DR, Beal MF (1996) Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71:1043–1048CrossRefPubMedGoogle Scholar
  30. Serteser M, Ozben T, Gumuslu S, Balkan S, Balkan E (2002) Lipid peroxidation in rat brain during focal cerebral ischemia: prevention of malondialdehyde and lipid conjugated diene production by a novel antiepileptic, lamotrigine. Neurotoxicology 23:111–119CrossRefPubMedGoogle Scholar
  31. Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT (1993) Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol Aging 14:295–301CrossRefPubMedGoogle Scholar
  32. Stefani A, Spadoni F, Bernardi G (1997) Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147:115–122CrossRefPubMedGoogle Scholar
  33. von Wegerer J, Hesslinger B, Berger M, Walden J (1997) A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 7:77–81CrossRefGoogle Scholar
  34. Williams AJ, Bautista CC, Chen RW, Dave JR, Lu XC, Tortella FC, Hartings JA (2006) Evaluation of gabapentin and ethosuximide for treatment of acute nonconvulsive seizures following ischemic brain injury in rats. J Pharmacol Exp Ther 318:947–955CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • S. Arpin
    • 1
    • 2
  • E. Lagrue
    • 1
    • 2
    • 3
  • S. Bodard
    • 1
  • S. Chalon
    • 1
    • 2
  • P. Castelnau
    • 1
    • 2
    • 3
    • 4
  1. 1.UMRS INSERM U 930, CNRS ERL 3106, “Imagerie et cerveau”ToursFrance
  2. 2.Université François Rabelais de ToursToursFrance
  3. 3.CHRU de Tours, Pôle de Pédiatrie Médicale, Unité de NeuropédiatrieHôpital ClochevilleToursFrance
  4. 4.Unité de Neuropédiatrie et UMRS INSERM U 930, CNRS ERL 3106, “Imagerie et cerveau”Université François Rabelais Laboratoire de Biophysique Médicale et PharmaceutiqueToursFrance

Personalised recommendations